KAPA

Kairos Pharma, Ltd. (KAPA) is a clinical-stage biopharmaceutical company headquartered in Los Angeles, California, focused on developing innovative therapies to meet critical unmet needs in oncology. The company boasts a promising pipeline of proprietary drug candidates aimed at improving cancer treatment outcomes, underscoring its commitment to advancing healthcare solutions. With a robust emphasis on research and development, Kairos Pharma is well-positioned to leverage the dynamic biopharmaceutical landscape, making it an attractive investment prospect for institutional investors seeking to engage in transformative advancements in cancer care.